{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:37:09Z","timestamp":1771666629772,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Importance: Since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic, Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV-2) infection has been a serious challenge for immune-compromised patients with immune-mediated inflammatory diseases (IMIDs). Objective: Our aim was to investigate the impact of COVID-19 in terms of risks of infection, hospitalization and mortality in a cohort of patients with rheumatoid arthritis (RA), psoriasis (PSO) or inflammatory bowel disease (IBD). Furthermore, we studied the impact of SARS-CoV-2 infection on the prescribed drug regimen in these patients. Methods: Through the record linkage between health information systems, a cohort of patients, \u226518 years old, assisted in the Lazio region and who had suffered from immune-mediated inflammatory diseases (RA, PSO, IBD) between 2007 and 2019, was identified. The risk of infection, hospitalization or mortality for COVID-19, was assessed by logistic regression models, and reported in an Odds Ratio (ORs; CI 95%), adjusting for sex, age and the Charlson Comorbidity Index. We also estimated these risks separately by IMID and in the subgroup of prevalent biologic drug users. We investigated deferral of biological treatments in the study population by comparing the prevalence of weekly use of biologicals (2019\u20132020) before and during the pandemic periods. Findings: Within the 65,230 patients with IMIDs, the cumulative incidence for COVID-19 was 303\/10,000 ab. In this cohort of patients, we observed a significantly higher risk of SARS-CoV-2 infection than the general population: OR = 1.17 (95% CI 1.12\u20131.22). The risk was higher even considering separately each disease and in the subgroup of prevalent biologic drug users. This last subgroup of patients showed a higher risk of death related to COVID-19 (OR 1.89; 95% CI 1.04\u20133.33) than the general population. However, no differences in terms of risks of hospitalization or death related to COVID-19 were recorded in patients with the IMIDs. Comparing the 2019\u20132020 prevalence of weekly biological drug treatments in prevalent biologic drug users, we found a decrease (\u221219.6%) during the lockdown, probably due to pandemic restrictions. Conclusions and Relevance: Patients with IMIDs seem to have a higher risk of SARS-CoV2 infection. However, other than for patients with prevalent biologic drug treatment, no significant differences in terms of hospitalization and mortality were reported compared to the general populations; further investigation is warranted on account of unmeasured confounding. In addition, during the lockdown period, the COVID-19 emergency highlighted a lower use of biologic drugs; this phenomenon requires strict pharmacological monitoring as it could be a proxy of forthcoming long-term clinical progression.<\/jats:p>","DOI":"10.3390\/jcm10112388","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:33:20Z","timestamp":1622201600000},"page":"2388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-443X","authenticated-orcid":false,"given":"Valeria","family":"Belleudi","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro C.","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-1901","authenticated-orcid":false,"given":"Francesca R.","family":"Poggi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5606-8712","authenticated-orcid":false,"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, 00149 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-4376","authenticated-orcid":false,"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[{"name":"National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, 00149 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-4641","authenticated-orcid":false,"given":"Andrea Picchianti","family":"Diamanti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sant\u2019Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nera","family":"Agabiti","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Lazio Regional Health Service, 00147 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Akiyama, S., Hamdeh, S., Micic, D., and Sakuraba, A. (2020). Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2020-218946"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102778","DOI":"10.1016\/j.autrev.2021.102778","article-title":"Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data","volume":"20","author":"Xu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_3","unstructured":"Ministero della Salute, Presidenza del Consiglio dei Ministri, Istituto Superiore di Sanit\u00e0, Agenzia Nazionale per i Servizi Sanitari Regionali, and Agenzia Italiana del Farmaco (2021, April 01). Vaccinazione anti-SARS-CoV-2\/COVID-19. Piano Strategico, Available online: http:\/\/www.salute.gov.it\/imgs\/C_17."},{"key":"ref_4","unstructured":"Department of Health and Social Care (2021, April 01). UK COVID-19 Vaccines Delivery Plan, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/951928\/uk-covid-19-vaccines-delivery-plan-final.pdf."},{"key":"ref_5","unstructured":"The Centers for Disease Control and Prevention (2021, April 01). The COVID-19 Vaccination Program Interim Operational Guidance for Jurisdictions Playbook, Available online: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/downloads\/COVID-19-Vaccination-ProgramInterim_Playbook.pdf."},{"key":"ref_6","unstructured":"European Centre for Disease Prevention and Control (2021, April 01). Overview of COVID-19 Vaccination Strategies and Vaccine Deployment Plans in the EU\/EEA and the UK. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/overview-implementation-covid-19-vaccination-strategies-and-vaccine-deployment."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Diamanti, A.P., Cattaruzza, M.S., Di Rosa, R., Del Porto, F., Salemi, S., Sorgi, M.L., Martin, L.S.M., Rai, A., Iacono, D., and Sesti, G. (2020). Psychological Distress in Patients with Autoimmune Arthritis during the COVID-19 Induced Lockdown in Italy. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111818"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Strangfeld, A., Sch\u00e4fer, M., Gianfrancesco, M.A., Lawson-Tovey, S., Liew, J.W., Ljung, L., Mateus, E.F., Richez, C., Santos, M.J., and Schmajuk, G. (2021). Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2021-220134"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies\u2014A Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B., Ahlenius, G.-M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad-D\u2019Elia, H., and Kastbom, A. (2021). Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide Swedish cohort study. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2021-219845"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Machado","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/art.41596","article-title":"American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3","volume":"73","author":"Mikuls","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41584-020-00562-2","article-title":"Rheumatic disease and COVID-19: Epidemiology and outcomes","volume":"17","author":"Hyrich","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00296-020-04566-9","article-title":"COVID-19, rheumatic diseases and immunosuppressive drugs: An appeal for medication adherence","volume":"40","author":"Venerito","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:50Z","timestamp":1760162990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10112388"],"URL":"https:\/\/doi.org\/10.3390\/jcm10112388","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}